|
We are now entering an era where genomics will touch every branch of medicine, ranging from oncology and rare diseases to infectious disease surveillance and preventive health. To support this shift, pipelines must be built not just for accuracy but for population-scale deployment, says Dr Vamsi Veeramachaneni, chief scientific officer, Strand Life Sciences.
He further adds that this requires cloud-native architectures that can handle millions of samples, AI-driven prioritisation to reduce interpretation times, continuous re-analysis as scientific knowledge updates, interoperability with hospital electronic systems, and auditability and traceability for regulators and clinicians. What we really need to be building is a digital public health backbone that integrates genomics seamlessly into everyday healthcare.
The future of healthcare will depend not just on reading genomes, but on understanding them at scale with the care, rigor, and humanity that patients deserve. Building scalable pipelines is therefore a priority, so that we can transform raw sequencing data into insights that can change lives, at a scale that changes healthcare. Modern sequencing platforms can read through entire genomes in hours. A single run can generate terabytes of data. This leads to a ‘data deluge’ problem, where sequencers run faster than humans can process it. Without intelligent, scalable pipelines, this data becomes unmanageable; useful only in theory, never in practice.
Veeramachaneni explains, “One can think of it as having every letter of a massive encyclopaedia, our genome, handed to us by sequencing machines. But what clinicians need is just one page, sometimes just one line, that explains what’s wrong with a patient. In order to extract that kind of information at scale, we need certain things. One, we need algorithms that sift through billions of data points flawlessly. Two, we need computation systems that expand as datasets grow. Three, we need analytics designed specifically for clinical decision-making. Four, there need to be quality control frameworks that eliminate ambiguity. And finally, we also need robust reporting systems that translate complexity into clarity.”
He further explains that the leap from research genomics to clinical genomics requires consistency. In research, variability may often be an inconvenience. In a clinic, it can seriously affect lives. Automated pipelines help solve this challenge. When every step, from raw read alignment to variant detection, annotation, interpretation, and reporting, is standardized and validated, the output becomes reproducible. This type of reliability builds the foundation for trust. For patients, this means clearer diagnoses, for clinicians, this means actionable insights, and for healthcare systems, this means scalability. Automation is what ensures that genomic medicine is not an artisanal craft but a dependable service.
“Before any insight can emerge, we must ensure that the biological signal we begin with is reliable. In this context, CancerSpot represents exactly the kind of advanced molecular chemistry and analytics that form the backbone of scaling genomics for real-world health use. Rather than focusing on DNA sequence alone, CancerSpot detects DNA methylation alterations - chemical marks on DNA that often change early in cancer cells. Blood-based tests like CancerSpot pick up fragments of DNA circulating in the bloodstream (called cell-free DNA), then use high-throughput sequencing and specialized analysis to flag methylation signatures associated with various cancers,” Veeramachaneni informs.
“What makes methylation-based detection especially powerful is that aberrant methylation is often one of the earliest hallmarks of cancer development, sometimes appearing long before structural mutations or visible tumours emerge. With robust technologies like methyl-seq and sensitive analytical pipelines, tests like CancerSpot can flag these early changes from a simple blood sample. That means early detection—when intervention has the greatest chance of success. In short, methylation-based molecular chemistry scanning regions across the genome, and refined analytics transforms cancer screening paradigms. It’s the foundation on which scalable, population-level cancer screening and early intervention can become a practical reality,” Veeramachaneni concludes.
|